Jeffrey L. Cleland PhD, BS

Dr. Cleland has 25 years of industry experience in research and development. He has played major roles in obtaining more then $500 million in capital including over $300 million raised as CEO of Versartis (VSAR), where he led one of the top biotech IPOs of all time. He has managed directly all aspects of pharmaceutical development and late-stage research. While at Genentech, he held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as early work on Lucentis®, Avastin®, Omnitarg® and Kadcyla®. He holds a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Cleland has authored more than 100 articles and 4 books, and holds several issued patents